A Phase 2 Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma
Phase of Trial: Phase II
Latest Information Update: 14 Jan 2019
At a glance
- Drugs Nivolumab (Primary) ; Sitravatinib (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- Sponsors Mirati Therapeutics
- 14 Aug 2018 Planned End Date changed from 30 Jun 2020 to 30 Sep 2020.
- 14 Aug 2018 Status changed from not yet recruiting to recruiting.
- 03 Aug 2018 New trial record